Notably, 7 of these samples were hormone receptor+/HER2–, while one was hormone receptor– and HER2+, suggesting an association between FGFR3 mutations and hormone receptor–positive breast cancer subtypes rather than TNBC. This evidence concerns the gene ERBB2 and breast cancer.